AR036674A1 - Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos - Google Patents
Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicosInfo
- Publication number
- AR036674A1 AR036674A1 ARP020103195A ARP020103195A AR036674A1 AR 036674 A1 AR036674 A1 AR 036674A1 AR P020103195 A ARP020103195 A AR P020103195A AR P020103195 A ARP020103195 A AR P020103195A AR 036674 A1 AR036674 A1 AR 036674A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- cycloalkylalkyl
- heteroaryl
- heterocycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 18
- 125000000217 alkyl group Chemical group 0.000 abstract 15
- -1 cyano, oximino Chemical group 0.000 abstract 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 10
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 7
- RFEBDZANCVHDLP-UHFFFAOYSA-N 3-[(4-cyanophenyl)methylamino]-6-(trifluoromethyl)quinoxaline-2-carboxylic acid Chemical compound OC(=O)C1=NC2=CC=C(C(F)(F)F)C=C2N=C1NCC1=CC=C(C#N)C=C1 RFEBDZANCVHDLP-UHFFFAOYSA-N 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000006682 monohaloalkyl group Chemical group 0.000 abstract 5
- 125000006684 polyhaloalkyl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 3
- 125000005110 aryl thio group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 2
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000005518 carboxamido group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto inhibidor de fosfodiesterasa V de guanina policíclico que tiene la formula (1) ó (2) o una sal o solvato del mismo farmacéuticamente aceptable, en la cual q = 0 ó 1; R1 es H, cicloalquilo, alquilo, R23-alquilo- ó R26; Ra, Rb y Rc son, independientemente uno del otro, cada uno H, alquilo, cicloalquilo, arilo, R22-arilo- ó R24-alquilo-; ó Ra y Rb, conjuntamente con el carbono al cual están ambos adheridos, forman un anillo de 4 a 7 miembros, y Rc es H ó alquilo; ó Ra y Rc, conjuntamente con los respectivos carbonos a los cuales están adheridos, forman un anillo de 4 a 7 miembros, y Rb es H ó alquilo; (i) X es un enlace; Y es H, R26 es cicloalquilo, alquilo, R25-alquilo- ó -(CH2)tTCOR100, donde t es 1 a 6, T es -O- ó -NH-, y R100 es H, R26, alquilo ó R26-alquilo-; y R2 es monohaloalquilo, polihaloalquilo, con la condición de que no debe ser trifluorometilo, azido, ciano, oximino, cicloalquenilo, heteroarilo, R22-heteroarilo- ó R27-alquilo-; (ii) X es un enlace; Y es Q-V, donde Q es un enlace ó alquilo C1-C8, y V es: (a) arilo sustituido con nitro, aminosulfonilo, ciano, monohaloalquilo, polihaloalquilo, con la condición de que no sea trifluorometilo, tiol, alquiltio, cicloalquilo, cicloalquilalquilo, -OCF3 ó aciloxi, y opcionalmente adicionalmente sustituido con 1 a 3 sustituyentes adicionales independientemente seleccionados del grupo que consiste en R21; (b) R22-heteroarilo-; ó (c) arilo ó heteroarilo, cada uno de los cuales está independientemente sustituido con 2 sustituyentes en átomos adyacentes del grupo V, que están unidos para formar un anillo carbocíclico o heterocíclico de 4 a 8 miembros fusionado no aromático, y opcionalmente adicionalmente sustituido con 1 a 2 sustituyentes adicionales independientemente seleccionados del grupo que consiste en R21; y es R2 es H, halo, -CONHR6, -CONR6R7, -CO2R6, monohaloalquilo, polihaloalquilo, azido, ciano,-C=N-OR6, cicloalquilo, cicloalquilalquilo, R26, aminosulfonilo, alquil ó R23-alquilo-; (iii) X es -O- ó -S-; Y se ha definido en la sección (i) anterior; y R2 es R26, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, cicloalquenilo ó R28-alquilo-; (iv) X es -O- ó -S-; Y se ha definido en la sección (ii) anterior; y R2 es alquilo, R26, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, cicloalquenilo ó R28-alquilo-; (v) X es -SO- ó -SO2-; Y se ha definido en la sección (i) ó (ii) anterior; y R2 es alquilo, R26, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, cicloalquenilo ó R28-alquilo-; (vi) X es -NR8-; Y se ha definido en la sección (i) anterior; y R2 es (R29)p-alquilo-, cicloalquilo, (R30)p-cicloalquilo-, cicloalquenilo, (R30)p-cicloalquenilo-, heterocicloalquilo ó (R30) p-heterocicloalquilo-; (vii) X es -NR8-; Y se ha definido en la sección (ii) anterior; y R2 es alquilo, R26, cicloalquilo, cicloalquilalquilo, heterocicloalquilo, cicloalquenilo ó R31-alquilo-; ó (viii) X es -C:::C-; Y se ha definido en la sección (i) ó (ii) anterior; y R2 es alquilo, R26, cicloalquilo, cicloalquilalquilo ó R23-alquilo-; donde, R6 es H ó R7; R7 es alquilo, cicloalquilo ó cicloalquilalquilo; R8 es heterocicloalquilo ó R6; R21 es 1-6 sustituyentes cada uno independientemente seleccionado del grupo que consiste en halo, hidroxi, alcoxi, fenoxi, fenilo, nitro, aminosulfonilo, ciano, monohaloalquilo, polihaloalquilo, tiol, alquiltio, cicloalquilo, cicloalquilalquilo, amino, alquilamino, acilamino, carboxilo, -C(O)OR34, carboxamido, -OCF3 y aciloxi; R22 es 1-6 sustituyentes cada uno independientemente seleccionado del grupo que consiste en alquilo y R21; R23 es cicloalcoxi, ariloxi, alquiltio, ariltio, cicloalquilo ó R28; R24 es cicloalquilo ó R26; R25 es hidroxi, alcoxi, amino, monoalquilamino, dialquilamino ó R26; R26 es arilo, R22-arilo-, heteroarilo ó R22-heteroarilo-; R27 es cicloalcoxi, ariloxi, alquiltio, ariltio, heteroarilo, R22-heteroarilo-, cicloalquilo, heterocicloalquilo, cicloalquenilo, cicloalquilamino ó heterocicloalquilamino; R28 es cicloalquilamino, heterocicloalquilamino ó R25; R29 es alcoxi, cicloalquilamino, heterocicloalquilamino ó R26 ; R30 es halo, hidroxi, alcoxi, amino, aminosulfonilo, ciano, monohaloalquilo, polihaloalquilo, tiol, alquiltio, alquilo, cicloalquilo, cicloalquilalquilo ó aciloxi; R31 es cicloalquilo ó R28; R34 es alquilo, arilo, aralquilo y heteroarilo; y p es 1 a 4; composiciones farmacéuticas y el uso de dichos compuestos para la preparación de medicamentos que son útiles para tratar disfunciones sexuales y otros desórdenes fisiológicos. Un ejemplo representativo es el compuesto de fórmula (3).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31539501P | 2001-08-28 | 2001-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036674A1 true AR036674A1 (es) | 2004-09-29 |
Family
ID=23224209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103195A AR036674A1 (es) | 2001-08-28 | 2002-08-26 | Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6969719B2 (es) |
| EP (1) | EP1421084B1 (es) |
| JP (2) | JP4450365B2 (es) |
| CN (2) | CN1781920A (es) |
| AR (1) | AR036674A1 (es) |
| AT (1) | ATE395349T1 (es) |
| CA (1) | CA2457944C (es) |
| DE (1) | DE60226615D1 (es) |
| ES (1) | ES2302835T3 (es) |
| MX (1) | MXPA04001891A (es) |
| PE (1) | PE20030415A1 (es) |
| WO (1) | WO2003020724A1 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| JP3945985B2 (ja) * | 2000-12-28 | 2007-07-18 | 株式会社リコー | デジタルカメラ装置 |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| JP2005504043A (ja) | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| CA2457944C (en) * | 2001-08-28 | 2009-09-29 | Schering Corporation | Polycyclic guanine phosphodiesterase v inhibitors |
| CA2459161A1 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
| JP2005509038A (ja) * | 2001-11-09 | 2005-04-07 | シェーリング コーポレイション | 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤 |
| MXPA04011862A (es) | 2002-05-31 | 2005-03-31 | Schering Corp | Procedimiento para preparar inhibidores xantina de la fosfodiesterasa v, y precursores de los mismos. |
| SI1509525T1 (sl) * | 2002-05-31 | 2006-12-31 | Schering Corp | Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev |
| DE10230311A1 (de) * | 2002-07-05 | 2004-01-22 | Degussa Ag | Verfahren zur Katalysator-freien Herstellung von O-Alkyl-N-cyanformimidaten |
| BRPI0416202A (pt) * | 2003-11-21 | 2006-12-26 | Schering Corp | formulações inibidoras de fosfodiesterase v |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| JP2008534505A (ja) * | 2005-03-25 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | テストステロンサプリメントおよび５アルファ−レダクターゼインヒビターによる男性の治療方法 |
| EP1888534B1 (en) | 2005-06-06 | 2017-07-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1896076A2 (en) * | 2005-06-27 | 2008-03-12 | Daniel Drai | Compositions and methods for enhancement of sexual function |
| US20070042957A1 (en) * | 2005-08-19 | 2007-02-22 | Mayo Foundation For Medical Education And Research | Type v phosphodiesterase inhibitors and natriuretic polypeptides |
| US20080194592A1 (en) * | 2005-08-23 | 2008-08-14 | Intra-Cellular Therapies, Inc. | Organic Compounds |
| WO2007070426A2 (en) * | 2005-12-09 | 2007-06-21 | Mayo Foundation For Medical Education And Research | Sexual dysfunction |
| JP2007290996A (ja) * | 2006-04-24 | 2007-11-08 | Ube Ind Ltd | ４−アミノテトラヒドロピランの製法 |
| EP2081431B1 (en) * | 2006-11-13 | 2013-01-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| MX2010000098A (es) * | 2007-06-21 | 2010-04-21 | Schering Corp | Derivados de guanina policiclicos y sus metodos de uso. |
| WO2009075784A1 (en) * | 2007-12-06 | 2009-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5701608B2 (ja) | 2007-12-06 | 2015-04-15 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP2358723B1 (en) | 2008-12-06 | 2015-05-13 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors |
| BRPI0922700A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| US8536159B2 (en) | 2008-12-06 | 2013-09-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2009322900A1 (en) * | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PE20110834A1 (es) | 2008-12-06 | 2011-12-14 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) |
| GEP20146046B (en) | 2008-12-06 | 2014-02-25 | Intracellular Therapies Inc | Organic compounds |
| CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| JP2012518685A (ja) * | 2009-02-25 | 2012-08-16 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 眼障害のためのｐｄｅ１阻害剤 |
| WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| SG10201507362TA (en) | 2009-08-05 | 2015-10-29 | Intra Cellular Therapies Inc | Novel Regulatory Proteins And Inhibitors |
| EP2523561A4 (en) * | 2009-12-22 | 2013-06-05 | Merck Sharp & Dohme | 7,8-DIHYDRO-1H-IMIDAZO [2,1-B] PURINE-4 (5H) -ONE DERIVATIVES AND METHOD OF USE |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| EP2576551A4 (en) | 2010-05-31 | 2014-04-16 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2956141A4 (en) | 2013-02-17 | 2016-10-26 | Intra Cellular Therapies Inc | NEW USES |
| DK2970279T3 (da) | 2013-03-15 | 2020-11-30 | Intra Cellular Therapies Inc | Organiske forbindelser |
| ES2871327T3 (es) | 2013-03-15 | 2021-10-28 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de enfermedades o trastornos de SNC o SNP |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| EP3177627B1 (en) | 2014-08-07 | 2019-07-24 | Intra-Cellular Therapies, Inc. | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3725789B1 (en) | 2014-09-17 | 2022-03-09 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
| KR102557603B1 (ko) | 2014-12-06 | 2023-07-19 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP6608933B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
| JP7401442B2 (ja) | 2018-01-31 | 2023-12-19 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| JP7612672B2 (ja) | 2019-09-03 | 2025-01-14 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規化合物 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| CN119039287A (zh) * | 2023-05-29 | 2024-11-29 | 中国药科大学 | 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1938016A1 (de) | 1969-07-23 | 1971-01-28 | Fischer Ohg Arzneimittelwerk | Verfahren zur Herstellung von 8-(N-Methyl-N-aethanolamin)-coffein als Arzneimittel gegen Erkaeltungskrankheiten |
| FR2116302A1 (en) | 1970-12-07 | 1972-07-13 | Brun Lab Sa Le | 8-aminotheophyllines - with coronary - vasodilator bronchodilator diuretic, spasmolytic, antiinflammatory and analgesic activity |
| EP0258191B1 (en) | 1986-08-28 | 1992-05-27 | Sandoz Ag | Xanthine derivatives |
| US5321029A (en) | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| FR2654935B1 (fr) | 1989-11-28 | 1994-07-01 | Lvmh Rech | Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux. |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| IL98559A0 (en) * | 1990-06-21 | 1992-07-15 | Schering Corp | Polycyclic guanine derivatives |
| GB9020921D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
| GB9020959D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
| DE69132291T2 (de) | 1990-12-21 | 2000-12-14 | Beecham Group P.L.C., Brentford | Xanthinderivate |
| GB9210839D0 (en) | 1992-05-21 | 1992-07-08 | Smithkline Beecham Plc | Novel compounds |
| GB9226532D0 (en) | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| IL108754A0 (en) | 1993-02-26 | 1994-06-24 | Schering Corp | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US5824683A (en) * | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US6037346A (en) | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| CA2309332C (en) | 1997-11-12 | 2002-12-03 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| DE19816857A1 (de) | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO1999062905A1 (en) | 1998-06-03 | 1999-12-09 | Almirall Prodesfarma, S.A. | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors |
| US6087362A (en) | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| US6023640A (en) | 1999-03-29 | 2000-02-08 | Ross; Jesse | Method contributing to obviating male impotency |
| US20020091129A1 (en) | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| CA2457944C (en) * | 2001-08-28 | 2009-09-29 | Schering Corporation | Polycyclic guanine phosphodiesterase v inhibitors |
-
2002
- 2002-08-26 CA CA002457944A patent/CA2457944C/en not_active Expired - Fee Related
- 2002-08-26 AR ARP020103195A patent/AR036674A1/es unknown
- 2002-08-26 WO PCT/US2002/027181 patent/WO2003020724A1/en not_active Ceased
- 2002-08-26 AT AT02761506T patent/ATE395349T1/de not_active IP Right Cessation
- 2002-08-26 EP EP02761506A patent/EP1421084B1/en not_active Expired - Lifetime
- 2002-08-26 MX MXPA04001891A patent/MXPA04001891A/es active IP Right Grant
- 2002-08-26 JP JP2003524994A patent/JP4450365B2/ja not_active Expired - Fee Related
- 2002-08-26 ES ES02761506T patent/ES2302835T3/es not_active Expired - Lifetime
- 2002-08-26 US US10/227,778 patent/US6969719B2/en not_active Expired - Fee Related
- 2002-08-26 CN CNA2005101248185A patent/CN1781920A/zh active Pending
- 2002-08-26 DE DE60226615T patent/DE60226615D1/de not_active Expired - Lifetime
- 2002-08-26 CN CNB028167066A patent/CN1315835C/zh not_active Expired - Fee Related
- 2002-08-27 PE PE2002000821A patent/PE20030415A1/es not_active Application Discontinuation
-
2005
- 2005-08-08 JP JP2005230176A patent/JP2005325138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1315835C (zh) | 2007-05-16 |
| CA2457944C (en) | 2009-09-29 |
| EP1421084B1 (en) | 2008-05-14 |
| EP1421084A1 (en) | 2004-05-26 |
| JP4450365B2 (ja) | 2010-04-14 |
| JP2005325138A (ja) | 2005-11-24 |
| JP2005502684A (ja) | 2005-01-27 |
| US6969719B2 (en) | 2005-11-29 |
| ATE395349T1 (de) | 2008-05-15 |
| US20030153587A1 (en) | 2003-08-14 |
| DE60226615D1 (es) | 2008-06-26 |
| CN1781920A (zh) | 2006-06-07 |
| WO2003020724A1 (en) | 2003-03-13 |
| CA2457944A1 (en) | 2003-03-13 |
| PE20030415A1 (es) | 2003-05-22 |
| CN1547583A (zh) | 2004-11-17 |
| ES2302835T3 (es) | 2008-08-01 |
| MXPA04001891A (es) | 2004-06-15 |
| HK1064668A1 (en) | 2005-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036674A1 (es) | Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos | |
| ES2150577T3 (es) | Aminoeteres aromaticos como agentes para aliviar el dolor. | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| AR050261A2 (es) | Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| AR035783A1 (es) | Compuesto, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular efectos de los receptores de histamina 3 | |
| AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
| AR029151A1 (es) | Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene | |
| AR000039A2 (es) | Compuestos de piridinosulfonamida sustituidos, composiciones herbicidas que los contienen, metodo para preparar estos compuestos y compuestosintermediarios. | |
| PE20050130A1 (es) | Compuestos organicos | |
| AR016822A1 (es) | Un compuesto derivado de amina ciclica, su uso, un proceso para fabricar compuestos utiles como intermediarios para fabricarlo, y una composicionfarmaceutica que lo comprende | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| ES2093367T3 (es) | Derivados de quinazolina. | |
| MX9202943A (es) | Compuestos triciclo, proceso para prepararlos y composicion farmaceutica que los contiene. | |
| EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
| CO5271658A1 (es) | Antagonistas del factor liberador de corticotropina | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| ES2037753T3 (es) | Compuestos heterociclicos y su preparacion y uso. | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
| PT96030A (pt) | Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem | |
| AR021068A1 (es) | Benzoilpiridazinas y procedimientos para elaborarlas; preparados farmaceuticos que las contienen y procedimiento para elaborarlos, y utilizacion de dichasbenzoilpiridazinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |